- Home
- RDCM vs MOLN Comparison
RDCM vs MOLN Comparison
Compare RDCM & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RDCM | MOLN |
|---|---|---|
| Founded | 1985 | 2004 |
| Country | Israel | Switzerland |
| Employees | 325 | N/A |
| Industry | Computer peripheral equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.1M | 147.5M |
| IPO Year | 1999 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RDCM | MOLN |
|---|---|---|
| Price | $10.23 | $3.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $14.00 | $10.36 |
| AVG Volume (30 Days) | ★ 54.3K | 2.0K |
| Earning Date | 11-11-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.56 | $450.00 |
| P/E Ratio | $16.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.40 | $3.52 |
| 52 Week High | $16.74 | $5.36 |
Technical Indicators
Market Signals| Indicator | RDCM | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 49.26 | 38.61 |
| Support Level | $10.07 | N/A |
| Resistance Level | $10.49 | $4.35 |
| Average True Range (ATR) | 0.22 | 0.17 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 61.40 | 10.83 |
Price Performance
Historical ComparisonAbout RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.